Jdrf’s Initiatives to Enhance Data Sharing and Collaboration in Diabetes Research

Juvenile Diabetes Research Foundation (JDRF) has long been a driving force in type 1 diabetes (T1D) research. While its early history focused on funding basic science and clinical trials, the organization has increasingly recognized that the path to a cure requires more than just funding—it requires breaking down silos between researchers, institutions, and even patients. Today, JDRF is pioneering initiatives that prioritize data sharing and collaborative research as essential tools for accelerating discovery. By creating infrastructure for secure data exchange and fostering global networks, JDRF is helping researchers ask bigger questions, validate findings faster, and ultimately deliver better outcomes for the T1D community.

Type 1 diabetes is a complex autoimmune disease influenced by genetic, environmental, and immunological factors. Understanding its onset, progression, and response to therapy requires analyzing vast amounts of data from diverse populations and study designs. Historically, research data has been scattered across individual laboratories, clinical trial sites, and private repositories, making it difficult to combine and compare results. This fragmentation hinders the identification of biomarkers, the replication of findings, and the development of personalized interventions.

JDRF recognized that to overcome these obstacles, the diabetes research community needed a cultural shift—moving from a competitive, data-hoarding mindset to one of open science and collaboration. The foundation’s initiatives aim to provide the tools, governance, and incentives necessary for researchers to share data responsibly while protecting patient privacy and intellectual property. These efforts align with broader trends in biomedical research, where funding agencies and journals increasingly require data sharing as a condition of support.

The JDRF Data Hub: A Centralized Secure Repository

One of the cornerstone initiatives is the JDRF Data Hub, a centralized platform designed to securely store and share de-identified clinical and research data from T1D studies. The Data Hub provides a standardized environment where researchers can upload datasets, apply controlled access permissions, and discover relevant data from other groups.

Key features of the JDRF Data Hub include:

Harmonized data standards: Datasets are transformed into common data models, making it easier to merge information from different sources (e.g., continuous glucose monitor outputs, C-peptide levels, genomic sequences).
Role-based access controls: Researchers can grant colleagues view-only, download, or analysis privileges, ensuring that sensitive data remains protected while enabling collaborative work.
Built-in analytics tools: The platform offers basic statistical and visualization capabilities, allowing researchers to run initial analyses without moving data to external systems.
Integration with existing databases: The Data Hub connects to other major repositories, such as the NIDDK Central Repository and the Type 1 Diabetes Genetics Consortium (T1DGC), reducing duplication of effort.

By lowering the technical barriers to data sharing, the JDRF Data Hub has accelerated several landmark studies. For example, a pooled analysis of clinical trial data from over 3,000 participants helped identify factors that predict progression to T1D in at-risk individuals, leading to more refined screening guidelines.

Diabetes Research Collaborative Networks

Beyond technology, JDRF invests heavily in building collaborative research networks that bring together investigators from academia, industry, and patient advocacy. These networks operate on the principle that complex problems like T1D require diverse expertise—from immunology and genomics to behavioral science and health informatics.

Three notable networks include:

The JDRF-New Frontier Consortium

This consortium focuses on identifying environmental triggers of T1D by linking large-scale epidemiological studies with high-resolution immunological monitoring. Researchers share dietary intake data, viral exposure records, and genetic profiles across multiple countries. The collaborative structure has enabled the consortium to publish joint analyses that would have been impossible for any single institution.

The Immune Tolerance Network (ITN) Partnership

JDRF partners with the ITN to design and execute innovative clinical trials aimed at inducing immune tolerance in newly diagnosed T1D patients. Within this partnership, data from placebo-controlled trials is rapidly made available to all ITN members after the primary analysis is complete, fostering secondary studies on biomarkers and subgroup responses.

The JDRF Artificial Pancreas Project Consortium

This network brings together engineers, clinicians, and data scientists to develop and refine closed-loop insulin delivery systems. Data from home-use trials—including sensor glucose readings, insulin delivery logs, and meal events—is shared among consortium members to improve algorithm performance. The collaborative model has been credited with shortening the time from bench to bedside for several commercial systems.

An often-overlooked dimension of data sharing is the involvement of patients. JDRF has been a founding supporter of the T1D Exchange, a patient registry and biobank that collects real-world data directly from people living with T1D. Participants contribute clinical data, lifestyle information, and blood samples, which are then de-identified and made available for research.

The T1D Exchange has become a valuable resource for understanding the lived experience of T1D, including challenges with glycemic control, access to technology, and mental health impacts. By giving patients a voice in the research process and enabling them to see how their data advances science, JDRF fosters a sense of partnership that is essential for long-term engagement.

To ensure that funded research maximizes its impact, JDRF implemented a mandatory Data Sharing Policy. All grantees receiving more than a threshold amount must submit their raw data and analytical code to the JDRF Data Hub or a comparable public repository within 12 months of study completion. The policy also requires that final manuscripts be made openly accessible in PubMed Central within 12 months of publication.

This policy has had ripple effects: it encourages meticulous record-keeping, facilitates peer review of results, and enables other researchers to replicate findings—a cornerstone of scientific rigor. JDRF is one of the few disease-specific foundations to enforce such a comprehensive sharing mandate, setting an example for other nonprofit research funders.

How These Initiatives Are Accelerating Diabetes Research

The practical impact of JDRF’s data sharing and collaboration programs can be seen across multiple domains of T1D research.

Discovery of Novel Biomarkers

By aggregating data from numerous small studies, researchers have been able to identify subtle patterns that were previously obscured. For instance, meta-analyses of gene expression datasets from pancreatic tissue samples revealed a previously unrecognized role for Type I interferon signaling in the early stages of beta-cell destruction. This finding has opened new avenues for therapeutic targeting, and the drug development pipeline now includes several compounds aimed at modulating the interferon pathway.

Accelerating Clinical Trial Recruitment and Design

Data sharing platforms enable researchers to mine historical trial data to design more efficient future studies. Using the JDRF Data Hub, a team at the University of Florida was able to identify inclusion criteria that enriched for fast progressors, reducing the required sample size for a prevention trial by nearly 30%. This saves resources and brings results to patients faster.

Improving Personalized Medicine Approaches

Combining genetic, immunological, and clinical data from the T1D Exchange and other sources has allowed researchers to stratify patients into subgroups with different disease trajectories. For example, children diagnosed before age 7 tend to have a more aggressive loss of C-peptide secretion compared to those diagnosed in adolescence. Clinical trials can now be designed to test interventions tailored to specific subgroups, improving the chances of success.

Enabling Real-World Evidence for Regulatory Decisions

The U.S. Food and Drug Administration (FDA) has increasingly accepted real-world evidence to support indications for medical devices and drugs. JDRF’s data networks provided critical real-world data that helped secure expanded indications for hybrid closed-loop insulin pumps. Regulators appreciated that the data came from a diverse, multi-site registry rather than a single clinical trial, increasing confidence in the results.

Challenges and Lessons Learned

While JDRF’s initiatives have been successful, they have not been without obstacles. Understanding these challenges offers valuable lessons for other organizations pursuing data sharing.

Privacy and Security Concerns

Patient data, even when de-identified, carries risks of re-identification. JDRF has invested heavily in robust data governance frameworks, including strict access logs, anonymization protocols, and training for researchers. The foundation also engages with patient advisory boards to ensure that data use policies align with community expectations.

Seasoned researchers sometimes resist sharing data before they have fully exploited it for publications and grants. JDRF addresses this by offering a one-year embargo period during which the original investigator retains exclusive access. Additionally, the foundation promotes a culture of recognition—data contributors are listed as co-authors on secondary analyses or acknowledged in publications.

Technical Interoperability

Harmonizing data from different sources remains a major technical challenge. JDRF funds the development of common data elements (CDEs) and has established partnerships with standards organizations like CDISC (Clinical Data Interchange Standards Consortium). Regular workshops bring together data managers to align variable definitions and coding systems.

Future Directions: Expanding the Ecosystem

Looking ahead, JDRF is doubling down on its commitment to data-centric research. The foundation plans to:

Expand the Data Hub internationally by partnering with European and Asian research consortia, enabling cross-continental data pooling for large-scale genetic and environmental studies.
Integrate wearable device data from continuous glucose monitors, fitness trackers, and smart insulin pens into the data ecosystem. This will provide high-resolution, longitudinal data that captures daily variability.
Launch a crowdsourced challenge platform where researchers can pose specific questions (e.g., “Predict which patients will achieve HbA1c < 7% within six months of starting a new pump”) and invite teams to compete using shared data. Cash prizes and recognition will incentivize participation.
Develop AI-powered analytics tools that run directly on the Data Hub, allowing researchers to apply machine learning without needing to export data. This will lower the barrier for labs with limited computational expertise.
Strengthen ties with industry while maintaining safeguards against commercial exploitation. JDRF is exploring models where pharmaceutical and device companies can access de-identified data in exchange for supporting the infrastructure and contributing their own clinical trial data.

Why This Matters for the T1D Community

For the millions of people living with type 1 diabetes, data sharing is not an abstract concept—it is a tangible pathway to better treatments and, ultimately, a cure. When researchers collaborate openly, they reduce duplication of effort, avoid costly dead ends, and identify promising therapies sooner. JDRF’s initiatives ensure that data collected from patients—often through their own participation in studies or registry contributions—works as hard as possible to advance science.

Moreover, by creating a culture of transparency and reproducibility, JDRF is helping to rebuild trust in biomedical research. Patients who donate their time, blood samples, and health data deserve to see that their contributions lead to measurable progress. The foundation’s emphasis on patient-centered data sharing and community engagement ensures that the T1D community remains at the heart of the research enterprise.

To learn more about JDRF’s data sharing policies and how to access these platforms, visit their official data sharing page. For those interested in the global movement toward open science in diabetes, the T1D Exchange and the NIDDK Central Repository are key resources. Finally, an overview of the ethical considerations tied to patient data in research can be found in this analysis from Nature Medicine.

Conclusion

JDRF has transformed from a traditional grant-making foundation into a catalyst for collaborative discovery. Through its Data Hub, research networks, patient registries, and mandatory sharing policies, the foundation has created an infrastructure that accelerates every step of the research pipeline—from basic science to clinical application. The path to a cure for type 1 diabetes is long, but with robust data sharing and collaboration, it is becoming clearer and more navigable every day. JDRF’s initiatives serve as a model for how philanthropic organizations can leverage the power of shared data to drive medical breakthroughs.